Ziekenhuis Gelderse Vallei Stichting
- Address
- lock Available on a paid plan
Ziekenhuis Gelderse Vallei Stichting - Advanced Cancer & Cardiovascular Research Center
Ziekenhuis Gelderse Vallei Stichting is a comprehensive clinical research center with extensive expertise in oncology and cardiovascular disease management. The center demonstrates particular strength in breast cancer research, conducting multiple trials examining targeted therapies including CDK 4/6 inhibitors, immunotherapy combinations, and novel treatment sequencing strategies for hormone receptor positive and triple negative breast cancer. The institution also maintains robust programs in gastrointestinal malignancies, hematologic disorders, and thoracic oncology, with a focus on precision medicine approaches.
- Breast cancer therapeutic strategies, including endocrine therapy optimization and immunotherapy combinations for metastatic disease
- Cardiovascular prevention and intervention trials, focusing on heart failure prevention, atherosclerotic disease management, and acute coronary syndrome treatments
- Hematologic malignancies, particularly chronic lymphocytic leukemia and multiple myeloma with emphasis on minimal residual disease-guided therapy
- Advanced colorectal and gastroesophageal cancers, including dose optimization strategies and novel chemotherapy combinations
The center's cardiovascular research portfolio encompasses innovative trials in heart failure prevention, lipid management, and acute myocardial infarction treatment. Additionally, the institution participates in respiratory disease research including acute respiratory distress syndrome (ARDS) and community-acquired pneumonia trials. The research program extends to metabolic disorders, investigating treatments for severe hypertriglyceridemia and obesity-related cardiovascular complications, demonstrating a comprehensive approach to modern chronic disease management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 15 therapeutic areas and 15 of 138 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 136 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 16 by active trials.
lock +15 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +13 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ziekenhuis Gelderse Vallei Stichting
lock Showing 1 of 55 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 | University Of Cologne | Phase III | Not Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 138 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 7 | Unknown | 2016-07-25 | 2026-07-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.